DMAB Trademark

Trademark Overview

On Friday, October 14, 2022, a trademark application was filed for DMAB with the United States Patent and Trademark Office. The USPTO has given the DMAB trademark a serial number of 97632191. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, December 3, 2024. This trademark is owned by Inovio Pharmaceuticals, Inc.. The DMAB trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations comprising nucleic acid encoded monoclonal antibody proteins produced in vivo for the treatment of cancers, genetic disorders, infectious diseases, and chronic diseases

General Information

Serial Number97632191
Word MarkDMAB
Filing DateFriday, October 14, 2022
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, December 3, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 22, 2024

Trademark Statements

Goods and ServicesPharmaceutical preparations comprising nucleic acid encoded monoclonal antibody proteins produced in vivo for the treatment of cancers, genetic disorders, infectious diseases, and chronic diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 18, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameInovio Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPlymouth Meeting, PA 19462
Party NameInovio Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPlymouth Meeting, PA 19462

Trademark Events

Event DateEvent Description
Tuesday, October 18, 2022NEW APPLICATION ENTERED
Tuesday, October 18, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, July 29, 2023ASSIGNED TO EXAMINER
Tuesday, August 8, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, August 8, 2023NON-FINAL ACTION WRITTEN
Tuesday, August 8, 2023NON-FINAL ACTION E-MAILED
Wednesday, November 8, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, November 8, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, April 18, 2024NOTICE OF REVIVAL - E-MAILED
Wednesday, February 21, 2024ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Wednesday, February 21, 2024ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Thursday, April 18, 2024TEAS PETITION TO REVIVE RECEIVED
Thursday, April 18, 2024PETITION TO REVIVE-GRANTED
Thursday, April 18, 2024TEAS PETITION TO REVIVE RECEIVED
Tuesday, September 10, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 10, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, September 10, 2024ASSIGNED TO LIE
Monday, September 16, 2024EXAMINERS AMENDMENT -WRITTEN
Monday, September 16, 2024EXAMINERS AMENDMENT E-MAILED
Monday, September 16, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, September 16, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, September 16, 2024EXAMINER'S AMENDMENT ENTERED
Wednesday, October 2, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 22, 2024PUBLISHED FOR OPPOSITION
Tuesday, October 22, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 3, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, April 18, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED

Related Keywords

dmab diseases cancers treatment genetic vivo disorders chronic infectious produced proteins